Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2023-09 Issue:10404 Volume:402 Page:775-785
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pozo-Rosich Patricia,Ailani Jessica,Ashina Messoud,Goadsby Peter J,Lipton Richard B,Reuter Uwe,Guo Hua,Schwefel Brittany,Lu Kaifeng,Boinpally Ramesh,Miceli Rosa,De Abreu Ferreira Rosa,McCusker Emily,Yu Sung Yun,Severt Lawrence,Finnegan Michelle,Trugman Joel M

Funder

AbbVie

Allergan

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. Migraine: epidemiology and systems of care;Ashina;Lancet,2021

2. Diagnosis and management of migraine in ten steps;Eigenbrodt;Nat Rev Neurol,2021

3. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates;Stovner;J Headache Pain,2022

4. Global prevalence of chronic migraine: a systematic review;Natoli;Cephalalgia,2010

5. Economic burden and costs of chronic migraine;Lanteri-Minet;Curr Pain Headache Rep,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis;Expert Opinion on Drug Safety;2024-09-12

2. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine;Expert Review of Neurotherapeutics;2024-09-12

3. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine;Headache: The Journal of Head and Face Pain;2024-09-09

4. Endometriosis: recent advances that could accelerate diagnosis and improve care;Trends in Molecular Medicine;2024-09

5. Migraine Treatment: When, Why, and How to Introduce Antimigraine Therapies;The Journal for Nurse Practitioners;2024-09